Similarly, experimental evidence strongly supports the tumorigenic potential of GOLPH3 overexpression and the anti-tumor effects of GOLPH3 silencing in various in vivo systems [15,19], including breast cancer [70] and glioma [71]. The gene discussed is GOLPH3; the disease is central nervous system cancer.